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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: HenocheScho¨nlein purpura (HSP) is the most common small vessel vas-
culitis in children. It is considered to be an IgA-containing immune complex-mediated disease.
Chemokines are small secreted proteins that attract leukocytes during inflammation. Our aim
was to determine the serum levels of chemokines and investigate the association of chemokine
gene polymorphisms with childhood HSP.
Methods: Serum levels of chemokines (interleukin-8/CXCL8, MCP-1/CCL2, RANTES/CCL5, MIG/
CXCL9, and IP-10/CXCL10) were determined using cytometric beads arrays. We investigated
the association of three single-nucleotide polymorphisms (SNPs) MCP1/CCL2 2518C/T,
RANTES/CCL5 403C/T, and RANTES/CCL5 28C/G with HSP in 85 HSP patients and 136
healthy controls.
Results: Five serum chemokine levels were significantly elevated in patients with the acute
stage of HSP compared to the normal controls (p < 0.05). MCP1/CCL2 2518 TT genotype
and T allele were associated with the risk for HSP with OR (95% CI) 3.32 (1.45e7.59) and
1.78 (1.20e2.64), respectively. The RANTES/CCL5 28 GG genotype was associated with a sig-
nificantly lower percentage of corticosteroid usage and lower corticosteroid accumulativet of Medical Research, National Taiwan University Hospital, Number 7, Chung-Shan South Road,
Taiwan, ROC.
tw (B.-L. Chiang).
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348 H.-H. Yu et al.dose in HSP patients. RANTES/CCL5 403 TC and TT genotype were significantly associated
with renal manifestations with an OR (95% CI) of 4.33 (1.44e12.99), adjusted for sex and
age and the other two SNP genotypes.
Conclusion: Our results support the fact that chemokines play important roles in the pathogen-
esis of HSP. MCP1/CCL2 gene polymorphisms were associated with susceptibility for HSP.
RANTES/CCL5 gene polymorphisms may be related to disease severity and HSP nephritis.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
HenocheScho¨nlein purpura (HSP) is the most common small
vessel vasculitis that occurs in children. It is an IgA-
containing immune complex-mediated vasculitis, which is
triggered by common viral or bacterial infections.1 The
European League Against Rheumatism (EULAR) proposed
consensus criteria for the classification of HSP in 2010,
which require individuals to have purpura or petechiae with
lower limb predominance and at least one of the four fol-
lowing criteria: abdominal pain, histopathology (typical
leukocytoclastic vasculitis or proliferative glomeruloneph-
ritis with predominant IgA deposits), arthritis or arthralgia,
or renal involvement (proteinuria > 0.3 g/day or hematuria
or red blood cell casts >5 red blood cells/high power field,
or 2þ on a dipstick).2
Perivascular accumulation of neutrophils in the acute
inflammatory lesions is the typical histopathological feature
of HSP, known as leukocytoclastic vasculitis. Lymphocyte and
monocyte/macrophage infiltration and neovascularization
are found later in the disease course.3 The mechanisms
underlying the perivascular leukocyte infiltrates and endo-
thelial damage in HSP are not fully understood. Previous
studies have shown the elevation of inflammatory mediators
in the serum of HSP patients, including tumor necrosis factor
(TNF)-a, interleukin-6, transforming growth factor (TGF)-b,
and vascular endothelial growth factor (VEGF).47 Genetic
variations in key inflammatory genes, including interleukin-1
beta (IL1B), interleukin-1 receptor antagonist (IL1RA),
intercellular adhesion molecule-1 (ICAM1), IL8, VEGF, and
TGFBgenepolymorphismsalsocontributeto the susceptibility
or different clinical manifestations in HSP.813
Proinflammatory chemokines are a group of small
secreted proteins that attract leukocytes to the inflam-
matory site and then activate them. It is a critical patho-
genic factor in tissue damage during the development of
vasculitis. Chemokine monocyte chemoattractant protein 1
(MCP-1/CCL2), and interferon gamma-induced protein-10
(IP-10/CXCL10) are strong chemoattractants for mono-
cytes/macrophages. Regulated upon activation, normal T-
cells expressed and secreted RANTES/CCL5, monokine
induced by gamma interferon (MIG/CXCL9), and IP-10/
CXCL10 are chemoattractants for T cells.14 The roles of
chemokines have been investigated in many rheumatic
diseases and vasculitis, such as Kawasaki disease, Behcet’s
disease, and polymyalgia rheumatica.1517 However, the
roles of proinflammatory chemokines except IL-8 have not
been investigated in HSP before.
We therefore aimed to investigate the changes in serum
levels of five different proinflammatory chemokines duringthe acute and convalescent stages of HSP. We tested the
association between serum chemokines levels at the acute
stage of HSP and disease severity. We also tested the
hypothesis that single nucleotide polymorphisms (SNPs) in
the MCP1/CCL2 and RANTES/CCL5 genes would be asso-
ciated with serum chemokine levels, disease susceptibility,
or severity.
Materials and methods
Study subjects
This study was conducted at National Taiwan University
Hospital, a tertiary referral center. Eighty-five patients who
were diagnosed with HSP, and 136 volunteersdhealthy,
sex-matched children (73 boys and 63 girls) aged 2e18
yearsdwere enrolled. The diagnosis of HSP was based on
the criteria defined by EULAR in 2010. Disease severity was
clinically assessed by the degree of systemic involvement.
Gastrointestinal involvement was defined as abdominal
pain with/without vomiting, and/or stool occult blood
1þ, and/or melena. Renal involvement was defined as per
the EULAR criteria of 2010. Informed consent and institu-
tional approval were obtained.
Serum and cytometric bead array
Serum was collected from 63 of the 136 age-matched
healthy controls, and 55 of 85 HSP patients in the acute
stage of HSP. Twenty HSP patients also donated blood
during the convalescent stage of HSP. The convalescent
stage was defined as the stage in which there was complete
resolution of symptoms and signs for 1 month after dis-
continuing medication. Serum concentrations of MIG/
CXCL9, IP-10/CXCL10, MCP-1/CCL2, RANTES/CCL5 and IL-
8/CXCL8 were analyzed by Human Chemokine Kit I Cyto-
metric Beads Array kits from BD Biosciences (San Diego, CA,
USA; BD CBA), according to the manufacturer’s recom-
mended protocols. The serum samples for RANTES/CCL5
were diluted 1:100 using the assay diluent to fit the con-
centration range.
DNA extraction and single nucleotide
polymorphism (SNP) genotyping
Genomic DNA of the 85 HSP patients and 136 controls was
extracted from the anticoagulated blood using a commer-
cially available DNA extraction kit (QIAGEN, QIAamp
DNA Blood Mini Kit, Germany) and stored at 20C
Table 1 Clinical characteristics and basic demographic
data of the 85 HSP patients.
HSP patients
Sex (male:female) 46:39 (1.18:1)
Age (years) 6.4  2.7
Previous infection history 51/84 (60.7%)
Purpura 85/85 (100%)
Gastrointestinal involvement 62/85 (72.9%)
Arthritis or arthralgia 60/85 (70.6%)
Renal involvement 30/85 (35.3%)
Central nervous system involvement 2/85 (2.4%)
Recurrence 9/85 (10.6%)
Steroid treatment 77/84 (91.7%)
Disease duration of 6 months or more 14/85 (16.5%)
IgA elevation 42/70 (60%)
Figure 1 Chemokine serum concentrations in the controls
and HSP patients in the acute stage. The serum chemokine
levels of MIG/CXCL9, IP-10/CXCL10, MCP-1/CCL2, RANTES/
CCL5, and IL-8/CXCL8 are significantly elevated in the acute
stage of HSP compared to the normal controls (p < 0.05).
*p < 0.01; **p < 0.0001. HSP Z HenocheScho¨nlein purpura.
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selecting well-investigated SNPs in chemokine genes
(MCP1/CCL2 2518 C/T (dbSNP ID rs1024611), RANTES/
CCL5 403 C/T (dbSNP ID rs2107538), and RANTES/
CCL5 28 C/G (dbSNP ID rs2280788) in a case control study
design. We chose these three previously identified common
functional variants from the National Center for Bio-
technology Information (NCBI) database (http://www.ncbi.
nlm.nih.gov/gene). Genotypes were identified by multiplex
polymerase chain reaction (PCR) and SNP analyses with the
GenomeLab SNPstream genotyping platform (Beckman
Coulter Inc. Fullerton, CA) and its accompanying SNPstream
software suite. The primers for the multiplex PCR and
single-base extension primers (tagged SNP primers) were
designed by the software provided by Beckman Coulter Inc.
The detailed methods, reagents, and PCR conditions were
described in a previous report.18 The direct sequencing
reactions using an ABI 3730 automated DNA sequencer
(Applied Biosystems, Foster City, CA) in 10 cases and 10
controls resulted in identical genotypes by multiplex PCR
and SNP analyses. The average genotype call rates by
multiplex PCR were 95.29% and 98.92%, respectively, for
the cases and controls. The overall genotype call rate was
98.32%.
Statistical methods
The ManneWhitney U test was used to compare the serum
chemokine levels between the groups of patients. A
paired t test was used to compare serum chemokine levels
in the acute and convalescent stage of HSP. A c2 goodness-
of-fit test was performed using the SAS/Genetics module,
version 9.1 (SAS Institute, Cary, NC) to assess whether the
observed genotype frequencies of each SNP marker
departed from the HardyeWeinberg equilibrium (HWE) in
the HSP patients and control subjects separately. After
the frequencies of the alleles and genotypes had been
calculated, Armitage’s trend and genotypic case-control
tests were determined with c2 tests using the SAS/
Genetics module to assess each SNP for a global associa-
tion with HSP. When the global association test was sig-
nificant, an unconditional logistic regression was
undertaken using SAS Proc LOGISTIC to calculate allele or
genotype odds ratios (OR) with 95% confidence intervals
(CIs) for the potential association between HSP and SNPs.
Logistic regression models were used to test the associa-
tion of genotypes with clinical outcomes. A p value of less
than 0.05 was considered to be statistically significant.
Power calculations were performed at a type 1 error rate
(a value) of 0.05 and a prevalence of 0.0001 for HSP using
the Genetic Power Calculator (http://pngu.mgh.harvard.
edu/wpurcell/gpc/). The prevalence was estimated
from the annual incidence of 12.9 per 100,000 children in
Taiwan.19
Results
Patient characteristics
The demographic data of the 85 children with HSP are
summarized in Table 1. All 85 (100%) patients had purpura,of whom 29 (34.1%) had prolonged purpura for 4 weeks or
more. Sixty-two (72.9%) patients had gastrointestinal (GI)
involvement, of whom 18 (21.2%) had GI bleeding. Thirty
(35.3%) patients had renal involvement, including 14
(16.5%) with severe nephropathy (nephrotic syndrome or
impaired renal function) and three (3.5%) with renal
sequelae (persistent urine abnormalities over 2 years).
Sixty percent of the HSP patients had serum IgA elevation at
disease onset.
Chemokine expressions in the HSP patients and
controls
The serum chemokine levels of MIG/CXCL9, IP-10/CXCL10,
MCP-1/CCL2, RANTES/CCL5 and IL-8/CXCL8 were sig-
nificantly elevated in patients with the acute stage of HSP
compared to the normal controls (p < 0.05) (Fig. 1). Com-
pared with the acute stage, serum chemokine levels
decreased significantly in the convalescent stage of HSP in
20 patients (p < 0.05), except for IL-8/CXCL8 (p Z 0.109)
and MIG/CXCL9 (p Z 0.805) (Fig. 2). There was more renal
involvement in the HSP patients with persistently elevated
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HSP patients with decreased MIG/CXCL9 levels in the con-
valescent stage (71.4% vs. 16.7%) (p Z 0.045).
Polymorphisms and HSP risk
Three SNPs and RANTES/CCL5 and MCP1/CCL2 genes were
investigated.Noneof theSNPdistributions showedadeviation
from the HardyeWeinberg equilibrium. Table 2 presents the
genotypes of the three SNPs for HSP patients (n Z 85) and
controls (n Z 136), as well as ORs for each of the SNPs.
MCP12518 TTand the TC genotype carried an increased risk
for HSP (OR (95% CI) 3.32 (1.45e7.59) and 2.0 (1.03e3.9),
respectively). After adjusting for age and sex, theadjustedOR
(95% CI) of MCP1 2518 TT and TC genotype remained
unchanged: 3.32 (1.45e7.59) and 2.01 (1.03e3.92), respec-
tively. The MCP1 2518 T allele carried an increased risk for
HSPwithanallelicOR (95%CI) of1.78 (1.20e2.64),p< 0.0001.
Chemokine expressions in the HSP patients with
different genotypes
Serum RANTES/CCL5 and MCP-1/CCL2 levels in the acute
stage of HSP did not significantly correlate with the corre-
sponding genotype (data not shown).
Factors associated with clinical outcomes in the
HSP patients
Patients with the RANTES/CCL5 28 G/G and C/G genotype
had a significantly lower percentage of corticosteroid usage
and lower corticosteroid accumulative dose (median dose
11.3 mg/kg vs. 20.5 mg/kg) (p Z 0.04) than patients
carrying the RANTES/CCL5 28C allele. The RANTES/
CCL5 403 TC and TT genotypes were associated with GIFigure 2 Chemokine serum concentrations in the HSP patients in
and IP-10 levels decrease significantly in the convalescent stage (pand renal involvement in the HSP patients (OR (95% CI) 2.97
(1.06e8.33) and 2.7 (1.06e6.85), respectively). However,
using multivariate logistic regression models adjusting for
age, sex, RANTES/CCL5 28G, RANTES/CCL5 403T, and
MCP1/CCL2 2518T genotypes, only the RANTES/
CCL5 403 TC and TT genotypes were associated with renal
involvement (OR (95% CI) 4.33 (1.44e12.99), p Z 0.009).
There was no significant association between clinical out-
comes and the RANTES/CCL5 28 GG and CG genotypes
(Table 3).Discussion
Our results showed significant elevations of the chemokines
MIG/CXCL9, IP-10/CXCL10, MCP-1/CCL2, RANTES/CCL5,
and IL-8/CXCL8 in the sera of patients with the acute stage
of HSP. Our finding suggests that proinflammatory chemo-
kines, which function in the recruitment of different types
of leukocytes, are involved in the pathogenesis of HSP. Our
results are consistent with a recent study that showed
elevation of serum levels of RANTES/CCL5, CXCL16, CX3CL1
in the acute stage of HSP,20 but contradictory to previous
reports of decreased IP-10/CXCL10 serum level or no ele-
vation of IP-10/CXCL10, MCP-1/CCL2, and Gro-a/CXCL1
levels in acute HSP.21,22
Recent studies have shown that chemokines are pro-
duced during inflammatory stimuli from endothelial cells.
Yang et al found that IgA antiendothelial cell antibodies in
the serum of HSP patients could stimulate human umbilical
vein endothelial cells (HUVECs) through extracellular signal-
regulated kinase (ERK) pathways to produce IL-8/CXCL8.6,23
Chen et al further showed that sera from patients with
active HSP could induce MCP-1/CCL2, RANTES/CCL5, IL-8/
CXCL8, CXCL16, and CX3CL1 production in HUVECs or the
human dermal microvascular endothelial cell line (HMEC-1)the acute and convalescent stage. The serum MCP-1, RANTES,
< 0.05). HSP Z HenocheScho¨nlein purpura.
Table 2 Association analysis between the SNPs of the MCP1/CCL2 and RANTES/CCL5 genes and HSP.
Gene SNP genotype HSPa (n Z 85) Controla (n Z 136) ORsb 95% CIb pb
MCP1 2518 C/T TT 21 (25.6%) 19 (14.0%) 3.32 1.45e7.59 0.005
TC 44 (53.7%) 66 (48.5%) 2.0 1.03e3.90 0.04
CC 17 (20.7%) 51 (37.5%) 1 d d
RANTES 403 C/T TT 10 (11.8%) 13 (9.6%) 0.92 0.34e2.53 0.88
TC 36 (42.4%) 54 (39.7%) 1.09 0.56e2.12 0.80
CC 39 (45.9%) 69 (50.7%) 1 d d
RANTES 28 C/G GG 2 (2.4%) 7 (5.1%) 0.33 0.03e3.29 0.35
GC 15 (17.6%) 22 (16.2%) 1.15 0.51e2.62 0.73
CC 68 (80%) 107 (78.7%) 1 d d
CI Z confidence interval; HSP Z HenocheScho¨nlein purpura; OR Z odds ratio; SNP Z single nucleotide polymorphism.
a The number of the patients along with the percentage in brackets.
b Logistic regression models are used to calculate OR and 95%CIs, and the corresponding p values for each genotype.
Chemokine MCP1 and RANTES gene polymorphisms in HSP 351through ERK and nuclear factor-kB (NF-kB) pathways.
Patients’ sera-stimulated HMEC-1 supernatants were also
noted to enhance leukocytes migration.20 These results
support the important role of chemokines in perivascular
leukocyte infiltrates and the vascular damage in HSP.
The genetic basis of HSP is unclear. To the best of our
knowledge, this is the first study to report an association of
MCP1/CCL2 2518T and the risk of susceptibility to HSP.
MCP-1 expression is inducible by proinflammatory cytokines
(TNF-a, IL-1b) through NF-kB in various cell types. The gene
expression of the MCP1/CCL2 2518C/T polymorphism in
the promoter region is controversial. Kim et al reported
that the T allele at 2518 was associated with upregulation
of MCP-1/CCL2.24 In contrast, Rovin et al and Gonzalez et al
reported that MCP1/CCL2 2518C produced more MCP-
1.25,26 These discrepancies may be related to differences in
disease or ethnicity. The MCP1/CCL2 2518TT genotype
has been shown to be an independent risk factor for the
progression of renal diseases in Japanese patients with IgA
nephropathy, which shares a common disease mechanism
with HSP nephritis.27 To elucidate the role of the MCP1/
CCL2 2518 gene polymorphism in HSP, the relationship
between the MCP1/CCL2 2518 genotype, MCP-1 pro-
duction from endothelial cells, and macrophage infiltration
in skin and other target organs such as the kidney should be
investigated in future studies.
Our results showed that the RANTES/CCL5 403 TC and
TT genotypes carried an increased risk of HSP nephritis.
RANTES/CCL5 403 C to T change results in a new binding
element for GATA transcriptional factors and has higher
transcriptional activity.28 The promoter of that RANTES/
CCL5 28 gene polymorphism site is close to the NF-kBTable 3 Frequency and ORs of RANTES/CCL5 genotypes in HSP
HSP involvement SNP Genotype Model 1a:O
GI RANTES 28 GGþCG 1.85 (0.48
RANTES 403 CTþTT 2.97 (1.06
Renal RANTES 28 GGþCG 0.98 (0.32
RANTES 403 CTþTT 2.7 (1.06
CI Z confidence interval; HSP Z HenocheScho¨nlein purpura; OR Z o
a Model 1: Crude ORs and 95% CIs.
b Model 2: Adjusted for age, sex, RANTES/CCL5 28, RANTES/CCL5binding site, which is located at position 32 and plays a
critical role in the upregulation of RANTES promoter
activity. Liu et al reported that RANTES/CCL5 28G
increases RANTES/CCL5 expression through the NF-kB
pathway in CD8þ T cells, CD4þ T cells, and monocytes/
macrophages.29 A recent study showed that TNF-like weak
inducer of apoptosis (TWEAK), a member of the TNF family,
can act as a regulator of NF-kB activation, enhance
RANTES/CCL5 and IL-8/CXCL8 production in HMEC-1 cells,
and promote leukocyte migration. Moreover, serum levels
of TWEAK were found to correlate with the severity of
HSP.30 Although serum RANTES levels in the acute stage of
HSP did not correlate with disease severity in our study
(data not shown), the association between RANTES
expression in tissues and disease severity needs further
research.
The major limitation of our study is the small sample
size, which makes it underpowered to detect associations
of the modest effects of gene polymorphisms. Our data
show that the MCP1 2518 C/T gene polymorphism was a
risk factor for susceptibility to HSP in ethnically Chinese
children (powerZ 0.7). Our results need to be validated in
further large scale studies.
In conclusion, chemokines are important in leukocyte
recruitment to the inflammatory site, and theymay promote
vascular damage in vasculitis. Our results show a significant
elevation of chemokines during the acute stage of HSP.
MCP1/CCL22518Twas associated with the development of
HSP. RANTES/CCL5 gene polymorphisms may be associated
with disease severity. RANTES/CCL5 403T carried an
increased risk for HSP nephritis.patients with different disease manifestations.
Rs (95% CI) p Model 2b: ORs (95% CI) p
e7.14) 0.38 1.03 (0.23e4.63) 0.97
e8.33) 0.038 2.58 (0.82e8.13) 0.11
e2.98) 0.968 0.59 (0.17e2.08) 0.41
e6.85) 0.037 4.33 (1.44e12.99) 0.009
dds ratio.
403, and MCP1/CCL2 2518 genotype.
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